Hamster Anti-Mouse CD103-BIOT

9007-83-4

Mouse

The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added. Store at 2- 8 °C.
The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN3. Store at 2-8 °C.
The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN3. Store at 2-8 °C.
The R-phycoerythrin (R-PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN3 and a stabilizing agent. Store at 2-8 °C. Do not freeze!
The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. Aliquot and store at or below -20 °C.
Protect conjugated forms from light. Aliquot and freeze the low endotoxin, azide-free product at -20 °C immediately upon receipt. Each reagent is stable for the period shown on the bottle label if stored as directed.

The CD103/ alpha IEL beta 7 integrin complex (Mr 160 and 115 kDa peptides).
CD103 is a member of the integrin series of adhesion molecules. This antigen defines a developmentally important subset of T cells, namely mucosal T cells including all IEL (intraepithelial lymphocytes) and ~20% of lamina propria T cells. Expression of CD103 is more restricted outside these mucosal organs, appearing at lower levels on T cell subsets of the lymph node, dendritic epidermis and periphery.1-3 In non-epithelial CD103+ T cells there is a bias toward expression on CD8+.cells. The 2E7 mAb exhibits antigen immunoprecipitation patterns similar if not identical to the rat anti-mouse CD103 mAb M290.1 The 2E7 mAb is reported to have signal-inducing activity in a redirected lysis assay and to co-stimulate IEL and CD8+ lymph node cells in conjunction with anti-TCR in vitro, which runs counter to the usual inhibition of CTL by anti-integrins.1 This co-stimulatory activity is also shared by the mAb M290.4 The property of costimulation is not unique to the mouse since the combination of anti-human alpha IEL plus anti-TCR will produce similar proliferation in human cells, with the exception that CD8+ cells are not stimulated.5